ArticleMovement disorders clinical practice
Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.
Article in Movement disorders clinical practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.Frontiers in aging neuroscience · 2026Article
- Neuroprotective properties of zinc oxide nanoparticles: therapeutic implications for Parkinson's disease.Bioscience reports · 2024Review
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
- Translational molecular imaging and drug development in Parkinson's disease.Molecular neurodegeneration · 2023Review
- Morphological basis of Parkinson disease-associated cognitive impairment: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis.International journal of molecular sciences · 2021Review
- The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study.Brain communications · 2021Article
- Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old.Journal of Alzheimer's disease : JAD · 2021Article
- The seed ofPharmaceutical biology · 2020Article
- The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson's Disease Dementia.Metabolites · 2020Article
- Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia.PloS one · 2020Article
- Patient-Derived Midbrain Organoids to Explore the Molecular Basis of Parkinson's Disease.Frontiers in neurology · 2020Review
- Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease.Neurology · 2019Article
- Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease.PloS one · 2019Article
- Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Article
- The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.Journal of Alzheimer's disease & Parkinsonism · 2018Article
- Lychee Seed Fraction Inhibits Aβ(1-42)-Induced Neuroinflammation in BV-2 Cells via NF-κB Signaling Pathway.Frontiers in pharmacology · 2018Article
- Gray/White Matter Contrast in Parkinson's Disease.Frontiers in aging neuroscience · 2018Article
- Cognitive decline in Parkinson disease.Nature reviews. Neurology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNeuronal loss and α-synuclein (α-syn) pathology are diagnostic of PD in the appropriate clinical context. However, some PD patients have co-morbid Alzheimer's disease (AD) pathology on autopsy, including amyloid-β (Aβ) plaques and neurofibrillary tangles. Florbetapir(
objectiveTo determine the utility of florbetapir(
methodsFive participants with PDD had florbetapir(
resultsAll participants met neuropathological criteria for PD. Two had both positive florbetapir(
conclusionsFlorbetapir(
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.